Fibrinolytic response in subjects with hypertriglyceredemia and low HDL cholesterol

Biomedicine and Pharmacotherapy

Volumn 51, Issue 4, 1997, Pages 164-169

  Cimminiello, C ^a   Vigorelli, P ^a   Piliego, T ^b   Soncini, M ^a   Toschi, V ^a   Arpaia, G ^a   Perolini, S ^a   Bonfardeci, C ^a  

^a SAN CARLO BORROMEO HOSPITAL   (Italy)

^b Medical Department   (Italy)

Author keywords

fibrinolysis; gemfibrozil; HDL cholesterol; hypertriglyceridemia; insulin

Indexed keywords

GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; FIBRINOLYSIS; HUMAN; HYPERTRIGLYCERIDEMIA; MALE; PRIORITY JOURNAL; RISK FACTOR;

EID: 0030986696     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0753-3322(97)85585-0     Document Type: Article

References (23)

1. Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Am J Cardiol 1992;70:733-7
2. Austin MA. Plasma triglyceride and coronary heart disease. Arterioscler Thromb 1991;11:2-14
3. Avogaro P, Ghiselli G, Soldan S, Bittolo Bon G. Relationship of triglycerides and HDL cholesterol in Hypertriglyceridemia. Atherosclerosis 1992;92:79-86
4. Castelli WP. Epidemiology of triglycerides: a view from Framingham. Am J Cardiol 1992;70:3-9
5. Frick MH, Elo O, Haapa K et al. Helsinki Heart Study: primary-prevention trial with genfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987;317:1237-45
6. Fujii S, Sobel BE. Direct effect of gemfibrozil on the fibrinolytic system. Diminution of synthesis of Plasminogen Activator Inhibitor type 1. Circulation 1992;85: 1883-93
7. Fujii S, Sawa B, Sobel BE. Inhibition of endothelial cell expression of Plasminogen Activator Inhibitor type-1 by gemfibrozil. Thromb Haemost 1993;70:642-7
8. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High-density lipoprotein as protective factor against coronary heart disease: the Framingham Heart Study. Am J Med 1977;62:707-14
9. Gordon DJ, Probstfield JL, Garrison RJ et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989;79:8-15
10. Hamsten A, Wiman B, De Faire U, Blomback M. Increased plasma levels of a rapid inhibitor for tissue plasminogen activator in young survivors of myocardial infarction. N Eng J Med 1985;313:1557-63
11. Hamsten A, De Faire U, Walldius G et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987;ii:3-9
12. Juhan-Vague I, Vague P. Hypofibrinolysis and insulin-resistance. Diabete Metab 1991;17:96-100
13. Kluft C, Brakman P, Veldhuyzen-Stolk EC. Screening of fibrinolytic activity in plasma euglobulin fraction on the fibrin plate. In: Davidson JF et al. Progress in chemical Fibrinolysis and Thrombolysis. New York: Raven Press, 1979;57-65
14. Lipid Research Clinics Program: Manual of operations, Volume 1: Lipid and Lipoprotein Analysis. Bethesda, MD, NIH, NHLBI, DHEW publication No (NIH) 75-628, 1975;51-9
15. Medvescek M, Keber D, Stegnar M, Borovnicar A. Plasminogen Activator Inhibitor 1 response to a carbohydrate meal in obese subjects. Fibrinolysis 1990;42:84-90
16. Metha J, Metha P, Lawson D, Saldeen T. Plasma tissue plasminogen activator inhibitor levels in coronary disease: correlation with age and serum triglyceride concentrations. J Am Coll Cardiol 1987;9:263-8
17. Mussoni L, Mannucci L, Sirtori M et al. Hypertriglyceridemia and regulation of fibrinolytic activity. Arteriosclerosis Thromb 1992;12:19-27
18. National Diabetes Data Group: Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979;28:1039-57
19. Nguyen G, Horellou MH, Kruithof EKO, Conard J, Samama M. Residual Plasminogen Activator Inhibitor activity after venous stasis as a criterion for hypofibrinolysis: a study in 83 patients with confirmed deep vein thrombosis. Blood 1988;72:601-5
20. Oseroff A, Krishnamurti C, Hassett A, Tang D, Alving B. Plasminogen Activator and Plasminogen Activator Inhibitor activities in men with coronary artery disease. J Lab Clin Med 1989;113:88-93
21. Raccah D, Alessi MC, Scelels V et al. Plasminogen Activator Inhibitor Activity in various types of endogenous hypertriglyceridemia. Fibrinolysis 1993;7:171-6
22. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988;37:1595-607
23. Saku K, Ahmad M, Greenwalt-Glas P, Khashyap ML. Activation of fibrinolysis by apolipoproteins of high density lipoproteins in man. Thromb Res 1985;39:1-8